Moertel C G, Frytak S, Hahn R G, O'Connell M J, Reitemeier R J, Rubin J, Schutt A J, Weiland L H, Childs D S, Holbrook M A, Lavin P T, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas H O, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson J M, Zamcheck N, Novak J W
Cancer. 1981 Oct 15;48(8):1705-10. doi: 10.1002/1097-0142(19811015)48:8<1705::aid-cncr2820480803>3.0.co;2-4.
One-hundred-ninety-four eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU. Median survival with radiation alone was only 51/2 months from date of diagnosis. Both 5-FU-containing treatment regimens produced a highly significant survival improvement when compared with radiation alone. Forty percent of patients treated with the combined regimens were still living at one year compared with 10% of patients treated with radiation only. Survival differences between 4000 rads plus 5-FU and 6000 rads plus 5-FU were not significant with an overall median survival of ten months. Significant prognostic variables, in addition to treatment, were pretreatment performance status and pretreatment CEA level.
194例经组织学确诊为局部不可切除胰腺腺癌的合格且可评估患者被随机分配接受以下治疗:单纯高剂量(6000拉德)放射治疗、中等剂量(4000拉德)放射治疗 + 5-氟尿嘧啶(5-FU)以及高剂量放射治疗加5-FU。从诊断之日起,单纯放射治疗的中位生存期仅为5个半月。与单纯放射治疗相比,两种含5-FU的治疗方案均使生存期有显著提高。接受联合方案治疗的患者中有40%在一年时仍存活,而仅接受放射治疗的患者中这一比例为10%。4000拉德加5-FU与6000拉德加5-FU之间的生存差异不显著,总体中位生存期为10个月。除治疗外,重要的预后变量为治疗前的身体状况和治疗前癌胚抗原(CEA)水平。